Related Experiment Videos

[Hereditary deficit of antithrombin III]

Annales De Medecine Interne
|January 1, 1986
PubMed

Insights

Antithrombin III (AT III) deficiency, a common cause of thrombosis, presents as reduced AT III levels. Diagnosis involves heparin cofactor activity testing, with treatments including AT III concentrates and anticoagulants.

Area of Science:

  • Biochemistry
  • Hematology
  • Genetics

Background:

  • Antithrombin III (AT III) is a critical endogenous anticoagulant protein.
  • Heterozygous AT III deficiency leads to approximately 50% reduction in plasma concentrations.
  • This deficiency is a significant risk factor for thrombotic events.

Observation:

  • Clinical manifestations include deep venous thrombosis and pulmonary embolisms, often starting from puberty.
  • Both qualitative and quantitative forms of AT III deficiency are observed, with quantitative deficits being more prevalent.
  • Diagnosis requires assessing AT III activity in the presence of heparin, its cofactor.

Findings:

  • Reduced AT III levels (approximately 50%) characterize heterozygous deficiency.
  • A high percentage of patients (40-70%) experience thrombosis from puberty.
  • Heparin cofactor activity assay is essential for diagnosing both qualitative and quantitative deficits.

Implications:

  • Early diagnosis and management of AT III deficiency are crucial for preventing recurrent thrombotic events.
  • Treatment strategies involve AT III concentrates, heparin, and vitamin K antagonists.
  • Prophylactic AT III concentrate administration is recommended during high-risk procedures like surgery or delivery.

Related Concept Videos